Veru (VERU) surges 161.8% after disclosing Novo Nordisk Wegovy supply deal for obesity study

Veru Inc. (VERU) is up 161.8% today. Here is some analysis on what might have caused this price movement.

Analysis: The jump appears tied to an 8-K disclosure that Veru entered a clinical supply agreement with Novo Nordisk for Wegovy to support Veru’s Phase 2b PLATEAU obesity study evaluating enobosarm in combination with semaglutide. Investors may be reacting to the validation implied by a formal arrangement with a major GLP-1 manufacturer, plus the potential for future strategic optionality embedded in the agreement.

Details:

Veru disclosed it entered into a clinical supply agreement with Novo Nordisk on June 2, 2026 in connection with Veru’s Phase 2b PLATEAU study.

The PLATEAU study is designed to evaluate enobosarm (Veru’s oral selective androgen receptor modulator) in combination with Wegovy (semaglutide) in older adults with obesity receiving semaglutide for weight reduction.

Novo Nordisk will supply Wegovy at no charge for use in the study, while Veru remains responsible for sponsoring and conducting the trial.

The agreement grants Novo Nordisk a right of first negotiation if Veru later seeks to develop, commercialize, or license enobosarm IP in combination with Novo Nordisk GLP-1 products, which could be read as a pathway to deeper collaboration (speculation).

Sources:

U.S. SEC, Veru Investor Relations, Nasdaq

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$VERU Hedge Fund Activity

We have seen 19 institutional investors add shares of $VERU stock to their portfolio, and 36 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

PVG ASSET MANAGEMENT CORP removed 146,610 shares (-92.3%) from their portfolio in Q4 2025, for an estimated $313,745
ADAGE CAPITAL PARTNERS GP, L.L.C. removed 100,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $221,000
ENVESTNET ASSET MANAGEMENT INC removed 76,674 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $164,082
RENAISSANCE TECHNOLOGIES LLC added 69,250 shares (+inf%) to their portfolio in Q1 2026, for an estimated $153,042
CITADEL ADVISORS LLC removed 68,080 shares (-60.5%) from their portfolio in Q1 2026, for an estimated $150,456
NEWEDGE ADVISORS, LLC added 56,095 shares (+388.7%) to their portfolio in Q4 2025, for an estimated $120,043
JANE STREET GROUP, LLC removed 48,860 shares (-68.2%) from their portfolio in Q1 2026, for an estimated $107,980

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$VERU Price Targets

Multiple analysts have issued price targets for $VERU recently. We have seen 2 analysts offer price targets for $VERU in the last 6 months, with a median target of $24.5.

Here are some recent targets:

Leland Gershell from Oppenheimer set a target price of $24.0 on 05/15/2026
Edward Nash from Canaccord Genuity set a target price of $25.0 on 12/18/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.